BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 32747553)

  • 1. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.
    Li N; Kang Y; Wang L; Huff S; Tang R; Hui H; Agrawal K; Gonzalez GM; Wang Y; Patel SP; Rana TM
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20159-20170. PubMed ID: 32747553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M
    Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
    Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.
    Zhai J; Chen H; Wong CC; Peng Y; Gou H; Zhang J; Pan Y; Chen D; Lin Y; Wang S; Kang W; To KF; Chen Z; Nie Y; He HH; Sung JJ; Yu J
    Gastroenterology; 2023 Aug; 165(2):445-462. PubMed ID: 37169182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway.
    Jiang Y; Wan Y; Gong M; Zhou S; Qiu J; Cheng W
    J Cell Mol Med; 2020 Jun; 24(11):6137-6148. PubMed ID: 32329191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m
    Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
    EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m
    Tang B; Yang Y; Kang M; Wang Y; Wang Y; Bi Y; He S; Shimamoto F
    Mol Cancer; 2020 Jan; 19(1):3. PubMed ID: 31906946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
    Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
    Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.
    Qu J; Yan H; Hou Y; Cao W; Liu Y; Zhang E; He J; Cai Z
    J Hematol Oncol; 2022 Jan; 15(1):8. PubMed ID: 35063010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
    Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
    Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALKBH5-mediated m
    Hao L; Yin J; Yang H; Li C; Zhu L; Liu L; Zhong J
    Aging (Albany NY); 2021 Jan; 13(3):4045-4062. PubMed ID: 33428593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of m6A-factors METTL3, ALKBH5, and YTHDC1 alters HPV16 mRNA splicing.
    Cui X; Nilsson K; Kajitani N; Schwartz S
    Virus Genes; 2022 Apr; 58(2):98-112. PubMed ID: 35190939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk among writers, readers, and erasers of m
    Panneerdoss S; Eedunuri VK; Yadav P; Timilsina S; Rajamanickam S; Viswanadhapalli S; Abdelfattah N; Onyeagucha BC; Cui X; Lai Z; Mohammad TA; Gupta YK; Huang TH; Huang Y; Chen Y; Rao MK
    Sci Adv; 2018 Oct; 4(10):eaar8263. PubMed ID: 30306128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m
    Zhang S; Zhao BS; Zhou A; Lin K; Zheng S; Lu Z; Chen Y; Sulman EP; Xie K; Bögler O; Majumder S; He C; Huang S
    Cancer Cell; 2017 Apr; 31(4):591-606.e6. PubMed ID: 28344040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment.
    Dong F; Qin X; Wang B; Li Q; Hu J; Cheng X; Guo D; Cheng F; Fang C; Tan Y; Yan H; He Y; Sun X; Yuan Y; Liu H; Li T; Zhao Y; Kang C; Wu X
    Cancer Res; 2021 Dec; 81(23):5876-5888. PubMed ID: 34670781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
    Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
    Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N
    Zhu Z; Qian Q; Zhao X; Ma L; Chen P
    Gene; 2020 Mar; 731():144348. PubMed ID: 31927006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
    Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
    Front Immunol; 2022; 13():849592. PubMed ID: 35444654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression.
    You Y; Wen D; Zeng L; Lu J; Xiao X; Chen Y; Song H; Liu Z
    Int J Biol Sci; 2022; 18(13):5001-5018. PubMed ID: 35982895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.
    Yu F; Wei J; Cui X; Yu C; Ni W; Bungert J; Wu L; He C; Qian Z
    Nucleic Acids Res; 2021 Jun; 49(10):5779-5797. PubMed ID: 34048572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Radioactivity-Based Assay for Screening Human m6A-RNA Methyltransferase, METTL3-METTL14 Complex, and Demethylase ALKBH5.
    Li F; Kennedy S; Hajian T; Gibson E; Seitova A; Xu C; Arrowsmith CH; Vedadi M
    J Biomol Screen; 2016 Mar; 21(3):290-7. PubMed ID: 26701100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.